Spasmalgon, 2 ml 10 pcs

Spasmalgon cjlth;bn non-narcotic analgesic sodium metamizole, myotropic antispasmodic agent pitophenone and m-cholinoblocking agent phenpiveryinia bromide.

Pitophenone, like papaverine, has a direct myotropic effect on the smooth muscles of internal organs and causes them to relax.

Sodium metamizole is a derivative of pyrazolone. It has analgesic, antipyretic and anti-inflammatory action.

Phenpiperinia bromide has an additional relaxing effect on the smooth muscles due to its m-cholin-blocking action.

The combination of the three components of the drug leads to pain relief, relaxation of smooth muscles, and reduction of elevated body temperature.

Indications

can be used for short-term symptomatic treatment of: joint pain, neuralgia, sciatica, myalgia;
mild or moderate pain syndrome due to spasms of smooth muscles of internal organs: renal colic, hepatic colic, spasmodic pain along the intestine, algomenorrhea;
as an adjuvant it can be used to reduce pain after surgical and diagnostic interventions;
if necessary, the drug can be used to reduce elevated body temperature during colds and infectious and inflammatory diseases.

Pharmacological effect

Spazmalgon contains the non-narcotic analgesic metamizole sodium, the myotropic antispasmodic drug pitofenone and the m-anticholinergic drug fenpiverinium bromide.

Pitophenone – like papaverine, has a direct myotropic effect on the smooth muscles of internal organs and causes its relaxation.

Metamizole sodium is a pyrazolone derivative. It has analgesic, antipyretic and anti-inflammatory effects.

Phenpiverinium bromide – due to its m-anticholinergic effect, it has an additional relaxing effect on smooth muscles.

The combination of the three components of the drug leads to pain relief, relaxation of smooth muscles, and a decrease in elevated body temperature.

Special instructions

During treatment with the drug, you should not drink alcohol.

The use of the drug in nursing mothers requires cessation of breastfeeding.

The effect of the drug on the ability to drive vehicles and other mechanisms that require increased concentration

When using the drug, it is necessary to monitor the peripheral blood picture (leukocyte content) and the functional state of the liver.

If agranulocytosis is suspected or thrombocytopenia is present, the drug should be discontinued.

During treatment, it is not recommended to drive vehicles or engage in potentially hazardous activities that require quick physical and mental reactions.

Active ingredient

Metamizole sodium, Pitophenone, Fenpiverinium bromide

Composition

1 ml contains metamizole sodium 500 mg,

pitofenone hydrochloride 2 mg and fenpiverinium bromide 20 mcg.

Pregnancy

Contraindicated during pregnancy.

Breastfeeding should be stopped during treatment.

Contraindications

inhibition of bone marrow hematopoiesis;
stable and unstable angina;
hypersensitivity to pyrazolone derivatives (butadione, tribuzone), other components of the drug;
severe liver or kidney dysfunction;
chronic heart failure in the stage of decompensation;
tachyarrhythmia;
closed-angle form of glaucoma;
prostatic hyperplasia;
intestinal obstruction and megacolon;
granulocytopenia;
glucose-6-phosphate dehydrogenase deficiency;
pregnancy and lactation;
children under 6 years of age.

With caution: mild to moderate impairment of liver or kidney function; tendency to arterial hypotension (systolic pressure below 100 mmHg); tendency to bronchospasm; increased individual sensitivity to non-steroidal anti-inflammatory drugs or non-narcotic analgesics.

Side Effects

From the digestive system: burning sensation in the epigastric region, dry mouth.

From the nervous system: headache, dizziness, anticholinergic effects (decreased sweating, accommodation paresis, difficulty urinating).

From the cardiovascular system: decreased blood pressure, tachycardia, cyanosis.

From the urinary system: impaired renal function, oliguria, anuria, proteinuria, interstitial nephritis, red staining of urine.

From the hematopoietic organs: with long-term use – thrombocytopenia, leukopenia, agranulocytosis.

Allergic reactions: urticaria, bronchospastic syndrome, anaphylactic shock, Quincke’s edema, erythema multiforme (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell’s syndrome).

Interaction

Concomitant use with radiopaque drugs, colloidal blood substitutes and penicillin is contraindicated.

With simultaneous use of the drug with cyclosporine, the concentration of the latter in the blood decreases.

With simultaneous use of metamizole sodium, displacing oral hypoglycemic agents, indirect anticoagulants, corticosteroids and indomethacin from protein binding, increases their activity.

When used simultaneously, phenylbutazone, barbiturates and other inducers of microsomal liver enzymes reduce the effectiveness of metamizole sodium.

When used simultaneously with other non-narcotic analgesics, tricyclic antidepressants, oral hormonal contraceptives and allopurinol, increased toxicity may occur.

When used simultaneously, sedatives and anxiolytics (tranquilizers) enhance the analgesic effect of Spasmalgon.

When used simultaneously, thiamazole and cytostatics increase the risk of developing leukopenia.

When used simultaneously, the effect of the drug is enhanced by codeine, histamine H2 receptor blockers and propranolol (slow down inactivation).

When used simultaneously, drugs with myelotoxic effects enhance the hematotoxic effect of Spazmalgon.

When co-administered with histamine H1 receptor blockers, butyrophenones, phenothiazines, tricyclic antidepressants, amantadine and quinidine, the m-anticholinergic effect may be enhanced.

Use together with chlorpromazine or other phenothiazine derivatives can lead to the development of severe hyperthermia.

When used simultaneously, Spazmalgon enhances the effects of ethanol.

Pharmaceutical interactions

Due to the high likelihood of developing pharmaceutical incompatibility, it should not be mixed with other drugs in the same syringe.

Overdose

Symptoms: vomiting, dry mouth, decreased sweating, impaired accommodation, decreased blood pressure, drowsiness, confusion, impaired liver and kidney function, convulsions.

Treatment: gastric lavage, administration of activated carbon, symptomatic therapy.

Storage conditions

Store in a dry place, protected from light, at a temperature not exceeding 25°C.
Keep out of the reach of children.

Shelf life

3 years.

Manufacturer

Sopharma JSC, Bulgaria